The tweet was deleted by the author.
But we saved everything 🙂.
Editas Medicine will attend the 94th European Atherosclerosis Society Congress in Athens next week, where it plans to present new preclinical findings on its lead in vivo development candidate, EDIT-401.
The company aims to highlight advancements in therapies targeting atherosclerosis, with EDIT-401 positioned at the center of its latest research efforts. Attendees can expect detailed updates on the candidate's preclinical performance and strategic implications for future clinical development.
Editas Medicine has recently shared plans to present new preclinical data on its gene editing technologies at major scientific conferences, focusing on cardiovascular research initiatives such as EDIT-401 earlier this year. The company also released its first quarter 2026 results with a business update detailing progress in its gene editing programs last month. These updates provide additional context for Editas' strategy in advancing in vivo therapies.